Etanercept (Enbrel)

A recombinant version of soluble human TNF receptor fused to an IgG FC fragment that binds specifically to TUMOR NECROSIS FACTOR and inhibits its binding with endogenous TNF receptors. It prevents the inflammatory effect of TNF and is used to treat RHEUMATOID ARTHRITIS; PSORIATIC ARTHRITIS and ANKYLOSING SPONDYLITIS.

Also Known As:

Enbrel; Erelzi; Etanercept-szzs; Recombinant Human Dimeric TNF Receptor Type II-IgG Fusion Protein; TNF Receptor Type II-IgG Fusion Protein; TNFR-Fc Fusion Protein; TNR 001; TNR-001; TNT Receptor Fusion Protein; TNTR-Fc; Fusion Protein, TNFR-Fc; Recombinant Human Dimeric TNF Receptor Type II IgG Fusion Protein; TNF Receptor Type II IgG Fusion Protein; TNFR Fc Fusion Protein; TNR001

Networked: 4749 relevant articles (801 outcomes, 1020 trials/studies)

Relationship Network

Drug Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
- Peptides: 82426
  - Peptide Fragments: 373
    - Immunoglobulin Fragments: 976
      - Immunoglobulin Fc Fragments: 295
        Etanercept: 4749
        GP2015: 10
        etanercept biosimilar SB4: 8

Experts

1.	Dougados, Maxime: 37 articles (10/2022 - 07/2003)
2.	Emery, Paul: 32 articles (01/2021 - 01/2004)
3.	Vlahos, Bonnie: 30 articles (01/2021 - 06/2011)
4.	Feldman, Steven R: 28 articles (06/2022 - 11/2005)
5.	Gottlieb, Alice B: 27 articles (05/2022 - 11/2003)
6.	Curtis, Jeffrey R: 27 articles (11/2021 - 09/2010)
7.	Horneff, Gerd: 27 articles (11/2021 - 02/2007)
8.	Combe, Bernard: 23 articles (01/2022 - 07/2003)
9.	Freundlich, Bruce: 23 articles (02/2016 - 04/2007)
10.	van der Heijde, Désirée: 22 articles (01/2021 - 02/2004)

Related Diseases

1.	Psoriasis (Pustulosis Palmaris et Plantaris) 02/01/2009 - "To assess the cost-effectiveness of etanercept 50 mg biw for the treatment of chronic plaque psoriasis, and to explore characteristics of patients who benefited most from 50 mg dosing. " 09/01/2011 - "Marked improvement in nail psoriasis during treatment with etanercept." 06/01/2005 - "In previous studies, etanercept significantly improved plaque psoriasis and was well tolerated. " 04/01/2023 - "Etanercept ameliorates psoriasis progression through regulating high mobility group box 1 pathway." 05/01/2010 - "In conclusion, etanercept provided significant, sustained improvement in disease severity and was well tolerated in children > or = 8 years with severe plaque psoriasis."
2.	Rheumatoid Arthritis 01/01/2003 - "Overall, etanercept is highly effective and well tolerated by patients with PsA, with a safety profile similar to that seen in rheumatoid arthritis." 02/05/2016 - "The main aim of the VEDERA study (Very Early versus Delayed Etanercept in Rheumatoid Arthritis) is to assess the depth of remission, sustainability of remission and immunological normalisation induced by very early TNFi with etanercept (ETN) or standard of care +/- delayed ETN. " 02/05/2016 - "A prospective, single-centre, randomised study evaluating the clinical, imaging and immunological depth of remission achieved by very early versus delayed Etanercept in patients with Rheumatoid Arthritis (VEDERA)." 01/01/2019 - "A single-arm, open-label study to assess the immunogenicity, safety, and efficacy of etanercept manufactured using the serum-free, high-capacity manufacturing process administered to patients with rheumatoid arthritis." 01/01/2019 - "To evaluate the immunogenicity, safety, and efficacy of etanercept (ETN) manufactured using the serum-free, high-capacity manufacturing (SFHCM) process in patients with rheumatoid arthritis (RA). "
3.	Ankylosing Spondylitis 12/01/2011 - "Etanercept 50 mg weekly treatment of Chinese patients with active ankylosing spondylitis is convenient, fast-acting, highly effective, and well tolerated." 01/01/2004 - "In randomized, double-blind, placebo-controlled trials, subcutaneous etanercept 25mg twice weekly for 6-24 weeks significantly reduced disease activity in patients with active ankylosing spondylitis. " 04/01/2008 - "Rapid and sustained improvement in health-related quality of life and utility for 72 weeks in patients with ankylosing spondylitis receiving etanercept." 12/01/2006 - "Patients with ankylosing spondylitis can expect a comparable significant improvement in clinical outcomes with similar safety when treated with etanercept 50 mg once weekly or with 25 mg twice weekly." 05/02/2002 - "Treatment with etanercept for four months resulted in rapid, significant, and sustained improvement in patients with ankylosing spondylitis."
4.	Psoriatic Arthritis 01/01/2003 - "In the 24-week study, ACR20 response rates (50 vs 13%), psoriatic arthritis response rates (70 vs 23%) and the median improvement in skin lesions (33 vs 0%) were significantly greater in etanercept than in placebo recipients. " 01/01/2003 - "In patients with psoriatic arthritis, etanercept 25mg twice weekly significantly reduced disease activity and improved skin lesions in two double-blind, placebo-controlled, 12- to 24-week trials. " 01/01/2002 - "In the 24-week study, ACR20 response rates (50 vs 13%), psoriatic arthritis response rates (70 vs 23%) and the median improvement in skin lesions (33 vs 0%) were significantly greater in etanercept than in placebo recipients. " 01/01/2002 - "In patients with psoriatic arthritis, etanercept 25mg twice weekly significantly reduced disease activity and improved skin lesions in two double-blind, placebo-controlled, 12- to 24-week trials. " 04/01/2018 - "We realized a longitudinal open-label study to determine if increasing intervals between etanercept (ETN) administration could be effective in maintaining remission with a stable dose in a patient population affected by psoriatic arthritis (PsA) who had achieved sustained remission with ETN 25 mg biweekly. "
5.	Juvenile Arthritis (Juvenile Idiopathic Arthritis) 01/01/2011 - "Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis." 01/01/2019 - "The last case had a diagnosis of polyarticular juvenile idiopathic arthritis (JIA), successfully treated with etanercept, and has been in remission for 2 years. " 08/01/2009 - "Treatment with etanercept once weekly using a double dosage leads to a significant improvement of disease activity in patients with active polyarticular course juvenile idiopathic arthritis and is well tolerated." 01/01/2003 - "In patients with polyarticular-course juvenile rheumatoid arthritis, etanercept resulted in improvements in all measures of disease activity and was significantly more effective than placebo at reducing disease flare. " 01/01/2002 - "In patients with polyarticular-course juvenile rheumatoid arthritis, etanercept resulted in improvements in all measures of disease activity and was significantly more effective than placebo at reducing disease flare. "

Related Drugs and Biologics

1.	Infliximab (Remicade)
2.	Adalimumab (Humira)
3.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
4.	Methotrexate (Mexate)
5.	Etanercept (Enbrel)
6.	Ustekinumab (CNTO 1275)
7.	Tumor Necrosis Factor Inhibitors
8.	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)
9.	Proteins (Proteins, Gene)
10.	Antirheumatic Agents (DMARD)

Related Therapies and Procedures

1.	Therapeutics
2.	Biological Therapy
3.	Aftercare (After-Treatment)
4.	Drug Tapering
5.	Phototherapy (Light Therapy)